



## Pancreatic cancer trials open to recruitment - July 2025

This list includes trials targeted at pancreatic cancer alone and trials for many solid tumours which include pancreatic cancer. If you are a patient with pancreatic cancer and wish to discuss whether a clinical trial is right for you, please discuss with your treating Medical Oncologist.

**NOTE:** Trials listed are available for patients with pancreatic cancer to be referred for consideration. Several trials may have issues with slot availability or waitlists.

### Descriptive stages of pancreatic cancer

Medical Term	What it means
Resectable	This is an early stage of pancreatic cancer where the cancer can still be removed by surgery
Unresectable or locally advanced	The pancreatic cancer has not spread around the body but unfortunately the cancer cannot be removed by surgery due to the tumour size, location, or involvement of surrounding structures
Metastatic	The pancreatic cancer has spread to other parts of the body



<b>PANCREATIC CANCER TRIALS IN VICTORIA</b> (Trials with specific cohorts for pancreatic cancer)					
<b>Trial Title</b>	<b>Targets (Genomic)</b>	<b>Target population</b> <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	<b>Treatment + Further Information</b> <i>(What the study involves)</i>	<b>Site</b> <i>(Where the study is being offered)</i>	<b>Contact Details</b> <i>(Email the contact person listed with any enquiries)</i>
<b>NeoFOL-R</b>  Efficacy of Neoadjuvant FOLFIRINOX in Resectable pancreatic cancer: An international multicentre Randomized, controlled trial (NeoFOL-R) - Australian protocol	N/A	<b>RESECTABLE</b>  Exclusion: Borderline resectable Locally advanced Previous treatment for pancreatic cancer	<b>mFOLFIRINOX chemotherapy</b>  Arm A: Surgery then 12 cycles of chemotherapy  Arm B: 6 cycles of chemotherapy before surgery followed by 6 of cycles after surgery  Further information: <a href="#">NeoFOL-R - Victorian Cancer Trials Link</a>	Epworth Health	<a href="mailto:EJReissatiCentre@epworth.org.au">EJReissatiCentre@epworth.org.au</a>
				Monash Health	<a href="mailto:gi.oncresearch@monashhealth.org">gi.oncresearch@monashhealth.org</a>
				Western Health	<a href="mailto:CancerClinicalTrials@wh.org.au">CancerClinicalTrials@wh.org.au</a>
<b>DIRECT-InspIRE</b>  Investigation of the safety and efficacy of irreversible electroporation (IRE) using the NanoKnife® System in patients with unresectable stage 3 pancreatic cancer who have received 3 months of chemotherapy	N/A	<b>UNRESECTABLE (Stage 3)</b>  Inclusion: 3 months of chemotherapy (FOLFIRINOX or Gemcitabine based – 1 line only)	<b>NanoKnife System for Irreversible Electroporation (IRE)</b>  IRE is a technique using non-thermal energy to create permanent nanopores in the cell membrane in order to disrupt cellular homeostasis.  Further information: <a href="#">DIRECT/InspIRE Australia - Victorian Cancer Trials Link</a>	Peter MacCallum Cancer Centre	<a href="mailto:SurgicalResearchteam@petermac.org">SurgicalResearchteam@petermac.org</a>
				Alfred Health	<a href="mailto:charles.pilgrim@monash.edu">charles.pilgrim@monash.edu</a>
				Epworth Health	<a href="mailto:EJReissatiCentre@epworth.org.au">EJReissatiCentre@epworth.org.au</a>



<b>PANCREATIC CANCER TRIALS IN VICTORIA</b> (Trials with specific cohorts for pancreatic cancer)					
<b>Trial Title</b>	<b>Targets (Genomic)</b>	<b>Target population</b> <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	<b>Treatment + Further Information</b> <i>(What the study involves)</i>	<b>Site</b> <i>(Where the study is being offered)</i>	<b>Contact Details</b> <i>(Email the contact person listed with any enquiries)</i>
<b><u>AMG193 20230223</u></b>  A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination with Other Therapies in Subjects with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers with Homozygous MTAP-deletion AMG20230223	<b>MTAP deletion</b>	<b>METASTATIC/LOCALLY ADVANCED</b> <i>(All lines)</i>  Inclusion: Pancreatic cancer Homozygous MTAP-deletion  Exclusion: Prior MAT2A inhibitor or PRMT5 inhibitor	<b><u>AMG 193</u></b>  AMG 193 is a PMRT5 inhibitor which is administered orally. AMG 193 will be administered with chemotherapy.  Further information: <a href="https://trials.cancervic.org.au/details/vctlnct06360354">https://trials.cancervic.org.au/details/vctlnct06360354</a>	Peter MacCallum Cancer Centre	<a href="mailto:PCCTU.MoncC@petermac.org">PCCTU.MoncC@petermac.org</a>
				Austin Health	<a href="mailto:samantha.chakar@austin.org.au">samantha.chakar@austin.org.au</a>
				Epworth Health	<a href="mailto:EJreissaticentre@epworth.org.au">EJreissaticentre@epworth.org.au</a>
<b><u>PRISM-1</u></b>  A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients with Treatment-Naïve Metastatic Pancreatic Ductal Adenocarcinoma	<b>CD73</b>	<b>METASTATIC/LOCALLY ADVANCED</b> <i>(First line)</i> Inclusion: No prior treatment for metastatic disease  Exclusion: Prior treatment with CD72 antagonist or inhibitor Active autoimmune disease	<b><u>Quemliclustat</u></b>  Quemliclustat is CD73 inhibitor administered intravenously. Treatment: Chemotherapy (gemcitabine + nab-paclitaxel) + Quemliclustat or placebo  Further information: <a href="#">PRISM-1   Phase 3 Trial of Quemliclustat and Chemotherapy</a>	Monash Health	<a href="mailto:gi.oncresearch@monashhealth.org">gi.oncresearch@monashhealth.org</a>
<b><u>Clarity-PT01</u></b>  A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid	<b>CLDN18.2</b>	<b>METASTATIC/LOCALLY ADVANCED</b> <i>(First line)</i>  Inclusion: Pancreatic cancer Treatment naïve CLDN18.2 positive	<b><u>AZD0901</u></b> (antibody-drug conjugate)  AZD0901 targets and binds to CLDN18.2, which is a protein on tumour cells, and then delivers cytotoxic agents which damage these cancer cells.	Peter MacCallum Cancer Centre	<a href="mailto:PCCTU.MoncC@petermac.org">PCCTU.MoncC@petermac.org</a>



PANCREATIC CANCER TRIALS IN VICTORIA (Trials with specific cohorts for pancreatic cancer)					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
Tumours Expressing Claudin 18.2.		Exclusion: Exposure to prior CLDN18.2 targeted agents except anti- CLDN18.2 monoclonal antibody	Further information: <a href="https://trials.cancervic.org.au/details/vctlnct06219941">https://trials.cancervic.org.au/details/vctlnct06219941</a>		
<b>FMT</b>  Fecal Microbiota Transplantation to improve pain, symptom management and treatment efficacy in patients with pancreatic cancer	<b>N/A</b>	<b>METASTATIC/LOCALLY ADVANCED</b> (First line) Inclusion: Pancreatic cancer Treatment naïve (first line)  Exclusion: Antibiotic use within 8 weeks of randomisation (1 dose with ERCP allowed)	<u>Fecal Microbiota Transplantation</u>  Further information: <a href="https://www.pancreaticcentre.org.au/treatment/clinical-trials-and-research/fmt">https://www.pancreaticcentre.org.au/treatment/clinical-trials-and-research/fmt</a>	Epworth	<a href="mailto:EH-PancreaticCentre@epworth.org.au">EH-  PancreaticCentre@epworth.org.a  u</a>
<b>PemOla</b>  A phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with mismatch repair deficiency or tumour mutation burden > 4 mutations/ Mb	<b>dMMR/MS I-high or TMB &gt; 4 mutations / Mb</b>	<b>METASTATIC/LOCALLY ADVANCED</b> (First and second line) Inclusion: Pancreatic cancer	<u>Pembrolizumab and Olaparib</u>  Pembrolizumab in anti-PD1 antibody Olaparib is a PARP inhibitor  Further information: Contact trials unit Expected to open imminently	Monash Health	<a href="mailto:Gi.oncresearch@monashhealth.org">Gi.oncresearch@monashhealth.o  rg</a>



<b>PANCREATIC CANCER TRIALS IN VICTORIA</b> (Trials with specific cohorts for pancreatic cancer)					
<b>Trial Title</b>	<b>Targets (Genomic)</b>	<b>Target population</b> <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	<b>Treatment + Further Information</b> <i>(What the study involves)</i>	<b>Site</b> <i>(Where the study is being offered)</i>	<b>Contact Details</b> <i>(Email the contact person listed with any enquiries)</i>
<b><u>LuMIERE</u></b>  A Phase 1/2, Multicentre, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumour	<b>FAP</b>	<b>METASTATIC/LOCALLY ADVANCED</b> <i>(First and second line)</i>  Inclusion: Pancreatic ductal adenocarcinoma + other cancers  <u>Monotherapy Cohort:</u> Received at least 1 but no more than 2 lines of chemotherapy  <u>Combination cohort:</u> Chemotherapy naïve for advanced disease  Exclusion: Active CNS disease	<u>[177Lu]Lu-FAP-2286</u>  [177Lu]Lu-FAP-2286 is a radiopharmaceutical that targets fibroblast activation protein (FAP). This treatment works by binding to the FAP to allow the targeted delivery of radiation directly to FAP-expressing cancer cells.  [177Lu]Lu-FAP-2286 with or without chemotherapy  Further information: <a href="https://trials.cancervic.org.au/details/vctlnct04939610">https://trials.cancervic.org.au/details/vctlnct04939610</a>	Alfred Hospital	<a href="mailto:act-m@alfred.org.au">act-m@alfred.org.au</a>
<b><u>Porcupine P2EA</u></b>  An open-label study to assess the preliminary efficacy and safety of RXC004, (Zamaporvint), in patients with advanced pancreatic cancer who have progressed following therapy with current standard of care.	<b>Porcupine</b>	<b>METASTATIC/LOCALLY ADVANCED</b> <i>(Second line)</i>  Inclusion: Progression on first line treatment for incurable disease Mandatory biopsy at enrolment	<u>Zamaporvint</u>  Zamaporvint is an oral porcupine inhibitor. Treatment will be administered with denosumab  Further information: <a href="https://www.pancreaticcentre.org.au/treatment/clinical-trials-and-research/porcupine-p2ea">https://www.pancreaticcentre.org.au/treatment/clinical-trials-and-research/porcupine-p2ea</a>	Epworth	<a href="mailto:EH-PancreaticCentre@epworth.org.au">EH-PancreaticCentre@epworth.org.au</a>
<b><u>PAUF-I</u></b>  A First in Human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of	<b>PAUF</b>	<b>METASTATIC/LOCALLY ADVANCED</b> <i>(Second line +)</i>  Inclusion: Received at least 1 line of	<u>PBP1510</u>  PBP1510 is an IgG1 monoclonal antibody (mAb) that targets and neutralises PAUF.	Monash Health	<a href="mailto:earlyphase.oncresearch@monashhealth.org">earlyphase.oncresearch@monashhealth.org</a>



PANCREATIC CANCER TRIALS IN VICTORIA (Trials with specific cohorts for pancreatic cancer)					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
PBP1510 in Patients with Advanced/Metastatic Pancreatic Cancer		chemotherapy and progressed	Further information: <a href="https://trials.cancervic.org.au/details/vctlnct05141149">https://trials.cancervic.org.au/details/vctlnct05141149</a>		
<b><u>ALAFOSS-01</u></b>  A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0022 Monotherapy and in Combination With Anti-cancer Agents in Participants With Tumours Harboring a KRASG12D Mutation (ALAFOSS-01)	<b>KRAS G12D</b>	<b>METASTATIC/LOCALLY ADVANCED</b> (Second line +)  Inclusion: KRAS G12D mutation At least one prior line of treatment  Exclusion: Prior KRAS inhibitor	<b><u>AZD0022</u></b>  AZD0022 is an oral KRAS G12D inhibitor.  Further information: <a href="https://trials.cancervic.org.au/details/vctlnct06599502">https://trials.cancervic.org.au/details/vctlnct06599502</a>	Peter MacCallum Cancer Centre	<a href="mailto:PCCTU.EDD@petermac.org">PCCTU.EDD@petermac.org</a>
<b><u>INCB161734</u></b>  A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation	<b>KRAS G12D</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b> (Second line +)  Inclusion: Second line and beyond	<b><u>INCB161734</u></b>  INCB161734 in a KRAS G12D inhibitor  Further information: <a href="https://trials.cancervic.org.au/details/vctlnct06179160">https://trials.cancervic.org.au/details/vctlnct06179160</a>	Alfred Health	<a href="mailto:act-m@alfred.org.au">act-m@alfred.org.au</a>

**SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA**

<b>Trial Title</b>	<b>Targets (Genomic)</b>	<b>Target population (Trial suitable for patients with this stage of pancreatic cancer)</b>	<b>Treatment + Further Information (What the study involves)</b>	<b>Site (Where the study is being offered)</b>	<b>Contact Details (Email the contact person listed with any enquiries)</b>
<b><u>ADCE-T02-001</u></b>  First-in-Human, Phase 1 Study of AMT-754, a Targeting Tissue Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors	<b>Tissue Factor (TF)</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: Pancreatic cancer Received ≥1 prior line of therapy No further standard therapy available  Exclusion: Active CNS disease	<b>AMT-754</b>  AMT-754 is a targeting tissue factor antibody-drug conjugate (ADC). ADCs bind to a specific part of the surface of a cancer cell and then deliver targeted treatment directly into the cell.  Further information: <a href="https://trials.cancervic.org.au/details/vctlnct06597721">https://trials.cancervic.org.au/details/vctlnct06597721</a>	Cabrini	<a href="mailto:clinicaltrials@cabrini.com.au">clinicaltrials@cabrini.com.au</a>
				Peninsula and South Eastern Haematology and Oncology Group	<a href="mailto:ag@paso.com.au">ag@paso.com.au</a>
<b><u>HERTHENA</u></b>  A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors	<b>Her3</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: Received 1 line of systemic therapy and progressed  Exclusion: Prior anti-Her3 treatment Prior irinotecan	<b>HER3-DXd</b>  HER3-DXd is a Her3 antibody- drug conjugate.  Further information: <a href="https://trials.cancervic.org.au/details/vctlnct06172478">https://trials.cancervic.org.au/details/vctlnct06172478</a>	Monash Health	<a href="mailto:gi.oncresearch@monashhealth.org">gi.oncresearch@monashhealth.org</a>
<b><u>PRT7732-01</u></b>  A Phase 1 Open-Label, Multi- Center, Safety and Efficacy Study of PRT7732, an Oral SMARCA2 Degradar, in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation	<b>SMARCA4</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: SMARCA4 mutation  Exclusion: Concomitant SMARCA2 mutation	<b>PRT7732</b>  PRT7732 is an oral SMARCA2 degrader.  Further information: <a href="#">A Study of PRT7732, an Oral SMARCA2 Degradar, in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation - Rare Cancers Australia</a>	Monash Health	<a href="mailto:earlyphase.oncresearch@monashhealth.org">earlyphase.oncresearch@monashhealth.org</a>





SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<b><u>HM-EZHI</u></b>  A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM97662 as a Single Agent in Patients With Advanced or Metastatic Solid Tumors	<b>SWI/SNF Complex aberration (ARID1A SMARCA4 SMARCA2)</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: SW/SNF Complex aberration (ARID1A, SMARCA4, SMARCA2)  Exclusion: Prior valemestostat or other EZH1/2 inhibitor use	<b>HM97662</b>  HM97662 is an oral medication (EZH1/2 dual inhibitor).  Further information: <a href="https://trials.cancervic.org.au/details/feed-cta-trial541">https://trials.cancervic.org.au/details/feed-cta-trial541</a>	Monash Health	<a href="mailto:earlyphase.oncresearch@monashhealth.org">earlyphase.oncresearch@monashhealth.org</a>
				Peninsula and Southeast Oncology	<a href="mailto:ag@paso.com.au">ag@paso.com.au</a>
				Grampians Health (Ballarat)	<a href="mailto:clinicaltrials@gh.org.au">clinicaltrials@gh.org.au</a>
<b><u>BGB 58067</u></b>  A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-58067, an MTA-Cooperative PRMT5 Inhibitor in Patients With Advanced Solid Tumors	<b>MTAP loss</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: MTAP loss (pre-screening available)  Exclusion: Prior treatment with PRMT5 or MAT2A inhibitor	<b>BGB-58067</b>  BGB-58067 is an MTA-Cooperative PRMT5 inhibitor.  Further information: <a href="https://trials.cancervic.org.au/details/nct06589596">NCT06589596 - Victorian Cancer Trials Link</a>	Monash Health   (Note: Austin Health is only recruiting GBM)	<a href="mailto:earlyphase.oncresearch@monashhealth.org">earlyphase.oncresearch@monashhealth.org</a>  <a href="http://lth.org">lth.org</a>
<b><u>BGB 53038</u></b>  A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of	<b>KRAS mutation or amplification (excluding</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: Evidence of KRAS mutation or wild-type amplification	<b>BGB-53038</b>  BGB-53038 is a pan-KRAS inhibitor.	Monash Health	<a href="mailto:earlyphase.oncresearch@monashhealth.org">earlyphase.oncresearch@monashhealth.org</a>  <a href="http://lth.org">lth.org</a>



**SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA**

<b>Trial Title</b>	<b>Targets (Genomic)</b>	<b>Target population</b> <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	<b>Treatment + Further Information</b> <i>(What the study involves)</i>	<b>Site</b> <i>(Where the study is being offered)</i>	<b>Contact Details</b> <i>(Email the contact person listed with any enquiries)</i>
BGB-53038, a Pan-KRAS Inhibitor, As Monotherapy or in Combinations in Patients with Advanced or Metastatic Solid Tumors with KRAS Mutations or Amplifications	<b>KRAS G12R)</b>	Exclusion: KRAS G12R mutation Prior treatment with other RAS targeting treatment	Further information: <a href="#">NCT06585488 - Victorian Cancer Trials Link</a>	Peter MacCallum Cancer Centre	<a href="mailto:PCCTU.EDD@petermac.org">PCCTU.EDD@petermac.org</a>
<b><u>YL211</u></b>  YL211-INT-101-01: A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors	<b>cMET</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: No further standard treatment options available	<b><u>YL211</u></b>  YL211 is a C-MET targeted antibody-drug conjugate (ADC) available for all tumour types for dose escalation where there is either a C-met aberration or where there is a biological rationale for C-met directed therapy. Further information: <a href="#">YL211-INT-101-01 - Victorian Cancer Trials Link</a>	Monash Health	<a href="mailto:earlyphase.oncresearch@monashhealth.org">earlyphase.oncresearch@monashhealth.org</a>
<b><u>MK-1084</u></b>  A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Subjects With KRASG12C Mutant Advanced Solid Tumors	<b>KRAS G12C</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: KRAS G12C mutation	<b><u>MK1084</u></b>  MK1084 is an oral KRAS G12C inhibitor.  Further information: <a href="#">MK-1084 - Victorian Cancer Trials Link</a>	Monash Health	<a href="mailto:earlyphase.oncresearch@monashhealth.org">earlyphase.oncresearch@monashhealth.org</a>



## SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<b><u>PRIMROSE</u></b>  A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours That Are MTAP Deficient	<b>MTAP deficient</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: At least 1 prior line of treatment and exhausted treatment options Archival or baseline tumour sample for MTAP testing  Exclusion: Prior PRMT5 inhibitor	<b>AZD3470</b>  AZD3470 is a novel, potent and selective second-generation PRT5 inhibitor.  Further information: <a href="#">PRIMROSE - Victorian Cancer Trials Link</a>	Peter MacCallum Cancer Centre	<a href="mailto:PCCTU.EDD@petermac.org">PCCTU.EDD@petermac.org</a>
<b><u>CS5001</u></b>  A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activities of CS5001, an Anti-ROR1 Antibody-Drug Conjugate, Used as A Single Agent and in Combination with Systemic Therapies in Patients with Advanced Solid Tumors and Lymphomas.	<b>ROR1</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: Progression on at least 1 prior line of systemic therapy ECOG 0-1	<b>CS5001</b>  CS5001 in an antibody drug conjugate targeting ROR1  Further information: <a href="https://www.pancreaticcentre.org.au/treatment/clinical-trials-and-research/cs5001">https://www.pancreaticcentre.org.au/treatment/clinical-trials-and-research/cs5001</a>	Epworth	<a href="mailto:connie.barlas@epworth.org.au">connie.barlas@epworth.org.au</a> or  <a href="#">EH- PancreaticCentre@epworth.org.au</a>
<b><u>MarkV</u></b>  A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309	<b>VISTA</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: Progressed on available prior lines of therapy	<b>PMC-309</b>  PMC-309 is an anti-VISTA monoclonal antibody  PMC-309 will be administered	Grampians Health (Ballarat)	<a href="mailto:clinicaltrials@gh.org.au">clinicaltrials@gh.org.au</a>



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
(Anti-VISTA), as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced or Metastatic Solid Tumors		Progressed on PD-1 or PD-L1 inhibitor immunotherapy  Exclusion: Prior anti-VISTA therapy	alone or in combination with pembrolizumab  Further information: <a href="https://trials.cancervic.org.au/details/vctl_nct05957081">https://trials.cancervic.org.au/details/vctl_nct05957081</a>	Cabrini	<a href="mailto:clinicaltrials@cabrini.com.au">clinicaltrials@cabrini.com.au</a>
<b><u>BGB -C354-101</u></b>  Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumours	<b>B7H3</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: Advanced or metastatic solid organ malignancy not amenable to curative intent treatment  Exclusion: History of ILD	<b><u>BGB-C354</u></b>  BGB-C354 is a B7H3 antibody-drug conjugate Patients are treated with or without tislelizumab (anti-PD1 antibody)  Further information: <a href="https://clinicaltrials.gov/study/NCT06422520">https://clinicaltrials.gov/study/NCT06422520</a>	St Vincents Melbourne	<a href="mailto:OncologyTrialCoordinators@svha.org.au">OncologyTrialCoordinators@svha.org.au</a>
<b><u>AT-0174-001</u></b>  A Phase I Study to Evaluate the Safety, Tolerability, Pharmacology, and Preliminary Efficacy of AT-0174 in Subjects with Advanced Solid Malignancies	<b>IDO1/TDO2</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: Progressed on available prior lines of therapy	<b><u>AT-0174</u></b>  AT-0174 is a novel dual inhibitor of IDO1/TDO2  Further information: <a href="https://trials.cancervic.org.au/details/vctl_actrn12623000956606">https://trials.cancervic.org.au/details/vctl_actrn12623000956606</a>	Grampians Health (Ballarat)  St Vincent's Hospital Melbourne	<a href="mailto:clinicaltrials@gh.org.au">clinicaltrials@gh.org.au</a>  <a href="mailto:OncologyTrialCoordinators@svha.org.au">OncologyTrialCoordinators@svha.org.au</a>

**SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA**

<b>Trial Title</b>	<b>Targets (Genomic)</b>	<b>Target population (Trial suitable for patients with this stage of pancreatic cancer)</b>	<b>Treatment + Further Information (What the study involves)</b>	<b>Site (Where the study is being offered)</b>	<b>Contact Details (Email the contact person listed with any enquiries)</b>
<b><u>IMPARP</u></b>  An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination with Tislelizumab in Patients With Advanced Tumours with Homologous Recombination Repair Defects	<b>HRD deficiency</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: Second line and beyond Molecular testing within 12 months Confirmed germline or somatic alteration in homologous recombination related gene	<u>Pamiparib and tislelizumab</u>  Pamiparib is a PARP1/2 inhibitor. Tislelizumab is an anti-PD1 antibody.  Further information: <a href="https://trials.cancervic.org.au/details/feed-cta-trial389">https://trials.cancervic.org.au/details/feed-cta-trial389</a>	Western Health	<a href="mailto:CancerClinicalTrials@wh.org.au">CancerClinicalTrials@wh.org.au</a>
<b><u>AKTive-001</u></b>  A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients with Advanced Solid Tumors with AKT1 E17K Mutation	<b>AKT E17K mutation</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: Exhausted standard of care therapies  Exclusion: Prior mTOR or PI3K inhibitors Presence of KRAS, NRAS, HRAS or BRAF genomic alterations	<u>ALTA2618</u>  ALTA2618 is an oral AKT E17K inhibitor  Further information: <a href="https://trials.cancervic.org.au/details/vct1_nct06533059">https://trials.cancervic.org.au/details/vct1_nct06533059</a>	Cabrini	<a href="mailto:clinicaltrials@cabrini.com.au">clinicaltrials@cabrini.com.au</a>
<b><u>AMT-676-01</u></b>  First-in-Human, Phase 1 Study of AMT-676, an Anti-CDH17 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors	<b>CDH17</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: Second or later line therapy	<u>AMT-676</u>  AMT-676 is an anti-CDH17 antibody drug conjugate.  Further information: <a href="https://trials.cancervic.org.au/details/vct1_nct06400485">https://trials.cancervic.org.au/details/vct1_nct06400485</a>	Cabrini	<a href="mailto:clinicaltrials@cabrini.com.au">clinicaltrials@cabrini.com.au</a>



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<b><u>D3S-001-100</u></b>  A Phase 1, Open Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S 001 Monotherapy in Subjects with Advanced Solid Tumors with a KRAS p.G12C Mutation	<b>KRAS G12C</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: KRAS G12C mutation  *Note pancreatic specific cohort has closed. Pancreatic tumour remains open with limited slots	<b><u>D3S 001</u></b>  D3S 001 is a KRAS G12C inhibitor  Further information: <a href="https://trials.cancervic.org.au/details/feed-cta-trial449">https://trials.cancervic.org.au/details/feed-cta-trial449</a>	Cabrini	<a href="mailto:clinicaltrials@cabrini.com.au">clinicaltrials@cabrini.com.au</a>
				Peter MacCallum Cancer Centre	<a href="mailto:PCCTU.EDD@petermac.org">PCCTU.EDD@petermac.org</a>
<b><u>S095035</u></b>  A Phase 1, Open-label, Multicenter Clinical Trial of S095035 (MAT2A Inhibitor) in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP	<b>MAT2A MTAP</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: Homozygous deletion of MTAP Second line and beyond	<b><u>S095035</u></b>  S095035 is an oral MAT2A inhibitor.  Further information: <a href="https://trials.cancervic.org.au/details/vctlnct06188702">https://trials.cancervic.org.au/details/vctlnct06188702</a>	Alfred Health	<a href="mailto:act-m@alfred.org.au">act-m@alfred.org.au</a>
<b><u>MoST-TAP</u></b>  A Single Arm, Open-label, Phase II Signal-seeking Trial of Tiragolumab and Atezolizumab in Patients With Advanced Solid Tumours	<b>TMB PD-L1 amp + expression TIL</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: Exhausted standard of care treatment options TMB ≥10 mt/Mb PD-L1 amplification > 6 copy number alterations PD-L1 TAP score ≥5% Tumour Infiltrating Lymphocytes (CD3+CD8+) ≥5%	<b><u>Tiragolumab and atezolizumab</u></b>  Tiragolumab is an anti-TIGIT Ab. Atezolizumab is an anti-PD-L1 antibody.  Further information: <a href="https://trials.cancervic.org.au/details/vctlnct06003621">https://trials.cancervic.org.au/details/vctlnct06003621</a>	Bendigo Health	<a href="mailto:cancerresearch@bendigohealth.org.au">cancerresearch@bendigohealth.org.au</a>

**SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA**

<b>Trial Title</b>	<b>Targets (Genomic)</b>	<b>Target population (Trial suitable for patients with this stage of pancreatic cancer)</b>	<b>Treatment + Further Information (What the study involves)</b>	<b>Site (Where the study is being offered)</b>	<b>Contact Details (Email the contact person listed with any enquiries)</b>
<b><u>KEYNOTE-F49</u></b>  A Phase 1a/1b, First-in-human, Open-label, Non-randomized, Multicenter, Dose-escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of IOS-1002 Administered Alone and in Combination With a PD-1 Monoclonal Antibody in Advanced Solid Tumors	<b>LILRB1 LILRB2 KIR3DL1 PD-1</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: Second or later line	<b>IOS-1002 +/- Pembrolizumab</b>  IOS-1002 binds to LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1 receptors on innate and adaptive immune cells that suppress immune responses when activated.  Pembrolizumab in anti-PD1 antibody.  Further information: <a href="https://trials.cancervic.org.au/details/feed-cta-trial528">https://trials.cancervic.org.au/details/feed-cta-trial528</a>	Bendigo Health	<a href="mailto:cancerresearch@bendigohealth.org.au">cancerresearch@bendigohealth.org.au</a>  <a href="https://trials.cancervic.org.au/details/feed-cta-trial528">g.au</a>
<b><u>SYLVER</u></b>  A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors (SYLVER)	<b>WRN dMMR MSI-h</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: Second or later line/exhausted treatment options	<b>GSK4418959 +/-PD-1 inhibitor</b>  GSK4418959 is an oral WRN-inhibitor. This is given as monotherapy or in combination with a PD-1 inhibitor.  Further information: <a href="https://trials.cancervic.org.au/details/vctl_nct06710847">https://trials.cancervic.org.au/details/vctl_nct06710847</a>	Peter MacCallum Cancer Centre	<a href="mailto:PCCTU.MoncB@petermac.org">PCCTU.MoncB@petermac.org</a>
<b><u>GDC-7035</u></b>  A Phase I/II Dose-Escalation and Expansion Study Evaluating the	<b>KRAS G12D</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>	<b>GDC-7035</b>  GD-7035 is a KRAS G12D inhibitor. Treatment will be	Peter MacCallum Cancer Centre	<a href="mailto:PCCTU.EDD@petermac.org">PCCTU.EDD@petermac.org</a>



## SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors With a KRAS G12D Mutation		Inclusion: KRAS G12D mutation	monotherapy or in combination with other anti-cancer treatments.  Further information: <a href="https://trials.cancervic.org.au/details/vctlnct06619587">https://trials.cancervic.org.au/details/vctlnct06619587</a>		
<b><u>RO7566802</u></b>  A Phase I, Open-Label, Multicenter, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	<b><math>\alpha\text{v}\beta 8</math> integrin</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: Second or later line	<b><u>RO7566802</u></b>  RO7566802 is a $\alpha\text{v}\beta 8$ integrin inhibitor delivered intravenously.  Further information: <a href="https://trials.cancervic.org.au/details/vctlnct06031441">https://trials.cancervic.org.au/details/vctlnct06031441</a>	Peter MacCallum Cancer Centre	<a href="mailto:PCCTU.EDD@petermac.org">PCCTU.EDD@petermac.org</a>
<b><u>MK-6837-001</u></b>  A Phase 1 Open-label, Multicenter Study of MK-6837 as Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors	<b>TROP2</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Exclusion: Uncontrolled HIV, Hepatitis B or C	<b><u>MK-6837 +/- pembrolizumab</u></b>  MK-6837 is a TROP2-MMAE antibody-drug conjugate delivered as monotherapy or in combination with PD-1 inhibitor pembrolizumab.  Further information: <a href="https://trials.cancervic.org.au/details/vctlnct06460961">https://trials.cancervic.org.au/details/vctlnct06460961</a>	Alfred Health	<a href="mailto:act-m@alfred.org.au">act-m@alfred.org.au</a>
<b><u>BG-C477</u></b>  A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to	<b>CEACAM5</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion:	<b><u>BG-C477</u></b>  BG-C477 is an antibody-drug conjugate targeting CEACAM5.	Alfred Health	<a href="mailto:act-m@alfred.org.au">act-m@alfred.org.au</a>





## SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients With Selected Advanced Solid Tumors		CEA >5	BG-C477 will be delivered as monotherapy or in combination with capecitabine and bevacizumab.  Further information: <a href="https://trials.cancervic.org.au/details/vctlnct06596473">https://trials.cancervic.org.au/details/vctlnct06596473</a>		
<b><u>AMT-562-01</u></b>  First-in-Human, Phase 1 Study of AMT-562, an Anti HER3 Antibody- Drug Conjugate, in Patients with Advanced Solid Tumors	HER3	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: Second line and beyond	<b><u>AMT-562</u></b>  AMT-562 is a novel HER3 targeting antibody drug conjugate.  Further information: <a href="https://trials.cancervic.org.au/details/vctlnct06199908">https://trials.cancervic.org.au/details/vctlnct06199908</a>	Cabrini	<a href="mailto:clinicaltrials@cabrini.com.au">clinicaltrials@cabrini.com.au</a>
<b><u>SNT1521</u></b>  A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors	PARP	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: Exhausted treatment options	<b><u>SNT1521</u></b>  SNT1521 is a PARP1 inhibitor.  Further information: <a href="https://trials.cancervic.org.au/details/vctlnct06220864">https://trials.cancervic.org.au/details/vctlnct06220864</a>	Monash Health	<a href="mailto:earlyphase.oncresearch@monashhealth.org">earlyphase.oncresearch@monashhealth.org</a>
<b><u>MYE-Symphony/MTX-TROP2-302</u></b>  A Phase 1, Open-Label, First-in- Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in	TROP2	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>	<b><u>MT-302</u></b>  MT-302 is an anti-TROP2-CD89 mRNA CAR therapy.  Further information: <a href="#">MYE Symphony - Victorian Cancer Trials Link</a>	Cabrini	<a href="mailto:clinicaltrials@cabrini.com.au">clinicaltrials@cabrini.com.au</a>

**SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA**

<b>Trial Title</b>	<b>Targets (Genomic)</b>	<b>Target population (Trial suitable for patients with this stage of pancreatic cancer)</b>	<b>Treatment + Further Information (What the study involves)</b>	<b>Site (Where the study is being offered)</b>	<b>Contact Details (Email the contact person listed with any enquiries)</b>
Adults With Advanced or Metastatic Epithelial Tumors					
<b><u>IKSUDA</u></b>  A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors	<b>HER2</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: HER2 IHC 1-3+ HER2 ISH negative and positive	<b><u>IKS014</u></b>  IKS014 is a HER2 targeting antibody drug conjugate.  Further information: <a href="https://trials.cancervic.org.au/details/vctl_nct05872295">https://trials.cancervic.org.au/details/vctl_nct05872295</a>	Peninsula and Southeast Oncology	<a href="mailto:ag@paso.com.au">ag@paso.com.au</a>
<b><u>LOXO-RAS-200001</u></b>  A Phase 1a/1b Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors	<b>KRAS G12C</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: KRAS G12C mutation	<b><u>LY3537982</u></b>  LY3537982 is a KRAS G12C inhibitor and will be administered as monotherapy or in combination with other systemic anticancer medications.  Further information: <a href="https://trials.cancervic.org.au/details/vctl_nct04956640">https://trials.cancervic.org.au/details/vctl_nct04956640</a>	Peninsula and Southeast Oncology	<a href="mailto:ag@paso.com.au">ag@paso.com.au</a>
<b><u>Stingray SR-8541A-001</u></b>  Phase 1, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of SR-8541A (ENPP1 Inhibitor) Administered Orally as Monotherapy in Subjects With	<b>ENPP1</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: Exhausted conventional treatment	<b><u>SR-8541A</u></b>  SR-8541A is an ENPP1 inhibitor.  Further information: <a href="https://trials.cancervic.org.au/details/vctl_nct06063681">https://trials.cancervic.org.au/details/vctl_nct06063681</a>	Peninsula and Southeast Oncology	<a href="mailto:ag@paso.com.au">ag@paso.com.au</a>



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA					
<b>Trial Title</b>	<b>Targets (Genomic)</b>	<b>Target population</b> <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	<b>Treatment + Further Information</b> <i>(What the study involves)</i>	<b>Site</b> <i>(Where the study is being offered)</i>	<b>Contact Details</b> <i>(Email the contact person listed with any enquiries)</i>
Advanced/Metastatic Solid Tumors					
<b><u>BAY3498264</u></b>  Phase 1 Study of a SOS1 Inhibitor, BAY 3498264, in Combination in Participants With Advanced KRASG12C-mutated Solid Tumors	<b>SOS1 KRAS</b>	<b>ADVANCED OR METASATIC SOLID CANCERS</b>  Inclusion: KRAS G12C mutation	<b><u>BAY3498264</u></b>  BAY3498264 is a SOS1 inhibitor. Treatment will be in combination with sotorasib.  Further information: <a href="https://trials.cancervic.org.au/details/vctlnct06659341">https://trials.cancervic.org.au/details/vctlnct06659341</a>	Peninsula and Southeast Oncology	<a href="mailto:ag@paso.com.au">ag@paso.com.au</a>
<b><u>AK138D1</u></b>  A First-in-human, Phase I Study of Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AK138D1 in the Treatment of Advanced Solid Tumors	<b>HER3</b>	<b>ADVANCED OR METASATIC SOLID CANCERS</b>  Inclusion: Exhausted conventional treatment	<b><u>Patritumab Deruxtecan</u></b>  Patritumab Deruxtecan an anti-HER3 Antibody drug conjugate  Further information: <a href="https://trials.cancervic.org.au/details/vctlnct06730386">https://trials.cancervic.org.au/details/vctlnct06730386</a>	Peninsula and Southeast Oncology	<a href="mailto:ag@paso.com.au">ag@paso.com.au</a>
<b><u>DT-7012-CLI-001</u></b>  Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors (DOMISOL)	<b>CCR8</b>	<b>ADVANCED OR METASATIC SOLID CANCERS</b>  Inclusion: Second or later line	<b><u>DT-7012</u></b>  DT-7012 is an anti-CCR8 antibody.  Further information: <a href="https://clinicaltrials.gov/study/NCT06819735">https://clinicaltrials.gov/study/NCT06819735</a>	Peninsula and Southeast Oncology	<a href="mailto:ag@paso.com.au">ag@paso.com.au</a>



SUPPORTIVE CARE TRIALS FOR PATIENTS WITH PANCREATIC CANCER IN VICTORIA					
<b>Trial Title</b>	<b>Targets (Genomic)</b>	<b>Target population</b> <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	<b>Treatment + Further Information</b> <i>(What the study involves)</i>	<b>Site</b> <i>(Where the study is being offered)</i>	<b>Contact Details</b> <i>(Email the contact person listed with any enquiries)</i>
<b><u>DINE-PC</u></b>  Dietetics Intervention and Nutritional Evaluation in Pancreatic Cancer Care (DINE-PC)	N/A	<b>ALL STAGES OF PANCREATIC CANCER</b>	<u>Dietetics counselling</u>  Further information: <a href="https://www.pancreaticcentre.org.au/treatment/clinical-trials-and-research/dine-pc">https://www.pancreaticcentre.org.au/treatment/clinical-trials-and-research/dine-pc</a>	Epworth	<a href="mailto:EH-PancreaticCentre@epworth.org.au">EH- PancreaticCentre@epworth.org.au</a>
<b><u>Super-QoL</u></b>  Supplemental Jejunal feeding to Improve Quality of Life (SuperQoL)	N/A	<b>METASTATIC/LOCALLY ADVANCED</b>	<u>Jejunal feeding</u>  Further information: <a href="https://www.pancreaticcentre.org.au/treatment/clinical-trials-and-research/superqol">https://www.pancreaticcentre.org.au/treatment/clinical-trials-and-research/superqol</a>	Epworth	<a href="mailto:EH-PancreaticCentre@epworth.org.au">EH- PancreaticCentre@epworth.org.au</a>

**Phase 1 Trials are offered in Victoria at the following locations:**

Study Site	Contact	Email	Phone
Alfred Hospital (Prahran VIC 3004)	Clinical Trial Team	<a href="mailto:moncACT1@alfredhealthconnect.onmicrosoft.com">moncACT1@alfredhealthconnect.onmicrosoft.com</a>	TBA
Austin Hospital (Heidelberg VIC 3084)	Samantha Chakar	<a href="mailto:samantha.chakar@austin.org.au">samantha.chakar@austin.org.au</a>	03 9496 3088
Barwon Health (Geelong VIC 3220)	Karen Aitken	<a href="mailto:cstu.manager@barwonhealth.org.au">cstu.manager@barwonhealth.org.au</a>	03 4215 2758
Cabrini Malvern (Malvern VIC 3144)	Rochelle Woods	<a href="mailto:rwoods@cabrini.com.au">rwoods@cabrini.com.au</a>	95083437
Epworth Hospital (Richmond VIC 3121)	Clinical Research Coordinator	<a href="mailto:ehjreissaticentre@epworth.org.au">ehjreissaticentre@epworth.org.au</a>	0448 842 680 or 03 9426 8880
PASO Medical (Frankston VIC 3199)	Albert Goikman Clinical Trials Manager	<a href="mailto:ag@paso.com.au">ag@paso.com.au</a>	03 91131307
Monash Health (Clayton VIC 3168)	Early Phase Research Study Coordinator	<a href="mailto:earlyphase.oncresearch@monashhealth.org">earlyphase.oncresearch@monashhealth.org</a>	0474 769 510
Peter MacCallum Cancer Centre (Parkville VIC 3052)	Enquiries Line Coordinator	<a href="mailto:clinicaltrials.enquiries@petermac.org">clinicaltrials.enquiries@petermac.org</a>	03 8559 7456 (9am-2pm, Mon-Fri)
St Vincent's Hospital (Fitzroy VIC 3065)	Nadia Ranieri	<a href="mailto:oncology.research@svha.org.au">oncology.research@svha.org.au</a>	03 9231 3167
Western Health (St Albans VIC 3021)	Heike Raunow	<a href="mailto:CancerClinicalTrials@wh.org.au">CancerClinicalTrials@wh.org.au</a>	03 83959136 or 0434915739

*For patients not eligible for any of the above trials, and who have pancreatic cancer that has progressed, are intolerant or are ineligible for standard of care treatments, please consider a phase 1 trial. Clinicians can email or phone the contact listed with any enquiries. Patients, please contact your treating Medical Oncologist if you wish to discuss phase 1 trials.*



PANCREATIC CANCER TRIALS OUTSIDE OF VICTORIA					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<b><u>IBI343</u></b>  A Phase 1a/b, Multicenter, Open-label, First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors	<b>Claudin 18.2</b>	<b>METASTATIC/LOCALLY ADVANCED</b>  Inclusion: Exhausted standard treatment options CLDN18.2 positive	<b><u>IBI343</u></b>  IBI343 is an ADC targeting claudin18.2  Further information: <a href="https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=13578">https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=13578</a>	The Kinghorn Cancer Centre (NSW)	<a href="mailto:rkent@stvincents.com.au">rkent@stvincents.com.au</a>
				Southern Medical Day Care Centre (NSW)	<a href="mailto:suetrials@smdcc.com.au">suetrials@smdcc.com.au</a>
<b><u>MT302</u></b>  A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in Adults with Advanced or Metastatic Epithelial Tumors	<b>TROP2</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: Progressive disease at baseline, refractory or relapsed to standard of care or who have declined standard therapy.	<b><u>MT302</u></b>  MT302 is an anti-TROP2-CD89 mRNA CAR therapy  Further information: <a href="https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=13719">https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=13719</a>	Scientia Clinical Research (NSW)	<a href="mailto:adrian.talarico@scientiaclinicalresearch.com.au">adrian.talarico@scientiaclinicalresearch.com.au</a>
				The Kinghorn Cancer Centre (NSW)	<a href="mailto:rkent@stvincents.com.au">rkent@stvincents.com.au</a>
				Westmead Hospital (NSW)	<a href="mailto:meenai.rai@health.nsw.gov.au">meenai.rai@health.nsw.gov.au</a>
				Linear Clinical Research LTD Nedlands (WA)	<a href="mailto:enquiries@linear.org.au">enquiries@linear.org.au</a>



PANCREATIC CANCER TRIALS OUTSIDE OF VICTORIA					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<b><u>CA233-0000/</u></b> <b><u>BMS-986484</u></b>  A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors	CD40/FAP	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Exclusion: History of ILD	<b><u>BMS-986484</u></b>  BMS-986484 (a CD40/FAP bispecific agonist) is delivered as monotherapy or in combination with nivolumab	St Vincent's Hospital Darlinghurst (NSW)	<a href="mailto:svhs.research@svha.org.au">svhs.research@svha.org.au</a>
				Lyell McEwin Hospital (SA)	<a href="mailto:Health.NALHNCancerResearch@sa.gov.au">Health.NALHNCancerResearch@sa.gov.au</a>
<b><u>Clarity-PT01</u></b>  A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2.	CLDN18.2	<b>METASTATIC/LOCALLY ADVANCED</b>  Inclusion: Pancreatic cancer Treatment naïve (first line) CLDN18.2 positive  Exclusion: Exposure to prior CLDN18.2 targeted agents except anti-CLDN18.2 monoclonal antibody	<b><u>AZD0901</u></b> (antibody-drug conjugate)  AZD0901 targets and binds to CLDN18.2, which is a protein on tumour cells, and then delivers cytotoxic agents which damage these cancer cells.  Further information: <a href="https://www.anzctr.org.au/TrialSearch.aspx#&amp;&amp;searchTxt=NCT06219941">https://www.anzctr.org.au/TrialSearch.aspx#&amp;&amp;searchTxt=NCT06219941</a>	Prince of Wales Hospital (NSW)	<a href="mailto:SESLHD-POW-CTRUreferrals@health.nsw.gov.au">SESLHD-POW-CTRUreferrals@health.nsw.gov.au</a>
<b><u>AMG193 20230223</u></b>  A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination with Other Therapies in Subjects with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers with Homozygous MTAP-deletion	MTAP deletion	<b>METASTATIC/LOCALLY ADVANCED</b>  Inclusion: Pancreatic cancer Homozygous MTAP-deletion  Exclusion: Prior MAT2A inhibitor or PRMT5 inhibitor	<b><u>AMG 193</u></b>  AMG 193 is a PMRT5 inhibitor which is administered orally.  AMG 193 will be administered with chemotherapy.  Further information: <a href="https://www.genescare.com">https://www.genescare.com</a>	Genesis Care Norths Shore (NSW)	<a href="mailto:admin.northshore@genesiscare.com">admin.northshore@genesiscare.com</a>





PANCREATIC CANCER TRIALS OUTSIDE OF VICTORIA					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
AMG20230223			<a href="#">/au/clinical-trials/listings/amg-193-20230223</a>		
<b><u>VVD-130850-001</u></b>  A FIH study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VVD-130850, as single agent and in combination with checkpoint inhibition, in participants with advanced solid and hematologic tumors.	STAT3	ADVANCED OR METASTATIC SOLID CANCERS	VVD130850  VVD130850 is a novel STAT3-inhibitor. Treatment will be as a monotherapy or in combination with checkpoint inhibition (pembrolizumab)  Further information: <a href="https://clinicaltrials.gov/study/NCT06188208?term=NCT06188208&amp;rank=1">https://clinicaltrials.gov/study/NCT06188208?term=NCT06188208&amp;rank=1</a>	Central West  Cancer Care  Centre (Orange  Hospital NSW)	<a href="mailto:bernadette.sheldon@health.nsw.gov.au">bernadette.sheldon@health.nsw.gov.au</a>
				Blacktown  Cancer &  Haematology  Centre (NSW)	<a href="mailto:raymond.tanganan@health.nsw.gov.au">raymond.tanganan@health.nsw.gov.au</a>
				Cancer  Research South  Australia (SA)	<a href="mailto:admin@crsa.au">admin@crsa.au</a>



PANCREATIC CANCER TRIALS OUTSIDE OF VICTORIA					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
				Gold Coast  University  Hospital (QLD)	<a href="mailto:CBDclinicaltrials@health.qld.gov.au">CBDclinicaltrials@health.qld.gov.au</a>  <a href="#">u</a>
				ICON Cancer  Research (South Brisbane QLD)	<a href="mailto:admin.southbrisbane@icon.team">admin.southbrisbane@icon.team</a>
<b><u>ALKOVE-1</u></b>  A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-to655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-to1)	<b>ALK</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: ALK rearrangement or activating ALK mutation	<b><u>NVL655</u></b>  NVL655 (neladalkib) is an oral selective ALK inhibitor.  Further information: <a href="https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=13595">https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=13595</a>	Royal North Shore Hospital NSW	PI: <a href="mailto:malinda.itchins@sydney.edu.au">malinda.itchins@sydney.edu.au</a>  Trial coordinator:  <a href="mailto:shirley.liang@health.nsw.gov.au">shirley.liang@health.nsw.gov.au</a>
<b><u>AT-0174-001</u></b>  A Phase I Study to Evaluate the Safety, Tolerability, Pharmacology, and Preliminary Efficacy of AT-0174 in Subjects with Advanced Solid Malignancies	<b>IDO1/TDO2</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: Progressed on available prior lines of therapy	<b><u>AT-0174</u></b>  AT-0174 is a novel dual inhibitor of IDO1/TDO2  Further information: <a href="https://www.anzctr.org.au/Trial">https://www.anzctr.org.au/Trial</a>	Royal North Shore Hospital (NSW)	PI:  <a href="mailto:helen.wheeler@health.nsw.gov.au">helen.wheeler@health.nsw.gov.au</a>  Trial Coordinator:  <a href="mailto:wengiong.yu@health.nsw.gov.au">wengiong.yu@health.nsw.gov.au</a>



PANCREATIC CANCER TRIALS OUTSIDE OF VICTORIA					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<b>BGB-58067</b>  A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-58067, an MTA-Cooperative PRMT5 Inhibitor in Patients With Advanced Solid Tumors	MTAP deficiency	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: Any treatment line	<b>BGB-58067</b>  BGB-58067 is a PMRT5 inhibitor  Further information: <a href="https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=14130">https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=14130</a>	Blacktown Cancer & Haematology Centre (NSW)	<a href="mailto:William.dAvigdor@health.nsw.gov.au">William.dAvigdor@health.nsw.gov.au</a>
<b>GeneScreen 5FU</b>  DPYD Genotype-guided dose Personalisation for Fluoropyrimidine prescribing in Cancer	DPYD	<b>SOLID CANCERS – ALL STAGES</b>  Inclusion: Intention to treat with Fluoropyrimidine (FP) containing chemotherapy as part of either curative or palliative chemotherapy regimens  Exclusion: Prior FP containing chemotherapy prior to study entry.	<b>DPYD genotyping</b>  Pre-emptive DPYD genotyping prior to commencing Fluoropyrimidine chemotherapy can allow oncologists to prophylactically reduce FP dosing to improve patient tolerance and safety.  Further information: <a href="#">ANZCTR - Registration</a>	Lake Macquarie Private Hospital (NSW)	<a href="mailto:ClinicalTrialsUnit.LMP@ramsayhealth.com.au">ClinicalTrialsUnit.LMP@ramsayhealth.com.au</a>
<b>MoST-TAP</b>  A Single Arm, Open-label, Phase II Signal-seeking Trial of Tiragolumab and Atezolizumab in Patients With Advanced Solid Tumours	TMB PD-L1 amp + expression TIL	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion: Exhausted standard of care treatment options TMB ≥10 mt/Mb PD-L1 amplification > 6 copy number alterations PD-L1 TAP score ≥5% TILs (CD3+CD8+) ≥5%	<b>Tiragolumab and atezolizumab</b>  Tiragolumab is an anti-TIGIT Ab. Atezolizumab in an anti-PD-L1 antibody.  Further information: <a href="https://www.clinicaltrials.gov/study/NCT06003621">https://www.clinicaltrials.gov/study/NCT06003621</a>	Royal Hobart Hospital	<a href="mailto:1eclinicaltrials@ths.tas.gov.au">1eclinicaltrials@ths.tas.gov.au</a>



PANCREATIC CANCER TRIALS IN SINGAPORE					
<b>Trial Title</b>	<b>Targets (Genomic)</b>	<b>Target population</b> <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	<b>Treatment + Further Information</b> <i>(What the study involves)</i>	<b>Site</b> <i>(Where the study is being offered)</i>	<b>Contact Details</b> <i>(Email the contact person listed with any enquiries)</i>
<b><u>LDOXIRI-PDAC-01</u></b>  A phase II study of metronomic capecitabine, oxaliplatin and UGT1A1 genotype-directed irinotecan in metastatic pancreatic cancer patients.	<b>NA</b>	<b>METASTATIC/LOCALLY ADVANCED</b>  Inclusion: Systemic Treatment naive or treatment exposed advanced pancreatic adenocarcinoma	<u>Metronomic capecitabine, oxaliplatin and UGT1A1 genotype directed irinotecan</u>  Further information: <a href="https://clinicaltrials.gov/study/NCT05929885?term=NCT05929885&amp;rank=1b">https://clinicaltrials.gov/study/NCT05929885?term=NCT05929885&amp;rank=1b</a>	National Cancer Centre Singapore	<a href="mailto:honey.shwe.sin@nccs.com.sg">honey.shwe.sin@nccs.com.sg</a>
A first in human study to evaluate the safety, tolerability, and pharmacokinetics, pharmacodynamics, and preliminary clinical activity of BAY 3713372, a novel 2 <sup>nd</sup> generation PRMT5 inhibitor in participants with MTAP deleted solid tumors	<b>MTAP loss</b>	<b>ADVANCED OR METASTATIC SOLID CANCERS</b>  Inclusion Systemic Treatment naive or treatment exposed advanced pancreatic adenocarcinoma Homozygous MTAP deletion	<u>BAY 3713372</u>  BAY 3713372 is a novel 2 <sup>nd</sup> generation PRMT5 inhibitor.  Further information: <a href="https://clinicaltrials.gov/study/NCT06914128">https://clinicaltrials.gov/study/NCT06914128</a>	National Cancer Centre Singapore	<a href="mailto:Wang.jue.lynn@nccs.com.sg">Wang.jue.lynn@nccs.com.sg</a>
A phase I/II Dose-Escalation and expansion study evaluating the safety, pharmacokinetics, and activity of GDC-7035 as a single agent and in combination with other anti-cancer therapies in	<b>KRAS G12D</b>	<b>METASTATIC/LOCALLY ADVANCED</b>  Inclusion: Systemic Treatment refractory KRAS G12D pancreatic adenocarcinoma	<u>GDC-7035</u>  GDC-7035 is a KRAS G12D inhibitor	National Cancer Centre Singapore	<a href="mailto:Ye.xin@nccs.com.sg">Ye.xin@nccs.com.sg</a>



PANCREATIC CANCER TRIALS IN SINGAPORE					
<b>Trial Title</b>	<b>Targets (Genomic)</b>	<b>Target population</b> <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	<b>Treatment + Further Information</b> <i>(What the study involves)</i>	<b>Site</b> <i>(Where the study is being offered)</i>	<b>Contact Details</b> <i>(Email the contact person listed with any enquiries)</i>
patients with advanced solid tumors with a KRAS G12D mutation					
<b><u>PAUF-I</u></b>  A first in human phase I/2A, multicentre, open label study of evaluating the safety, tolerability, pharmacokinetics, and efficacy of PBP1510 in patients with advanced/metastatic pancreatic cancer	<b>PAUF</b>	<b>METASTATIC/LOCALLY ADVANCED</b>  Inclusion: Systemic Treatment exposed pancreatic adenocarcinoma	<b><u>PBP 1510</u></b>  PBP 1510 is an anti-PAUF antibody  Further information: <a href="https://clinicaltrials.gov/study/NCT05141149">https://clinicaltrials.gov/study/NCT05141149</a>	National Cancer Centre Singapore	<a href="mailto:Goh.mui.leng@singhealth.com.sg">Goh.mui.leng@singhealth.com.sg</a>